MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD
We assign a fundamental rating of 7 out of 10 to MBX. MBX was compared to 22 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making MBX a very profitable company, without any liquidiy or solvency issues. MBX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make MBX suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year MBX was profitable.
In the past year MBX had a positive cash flow from operations.
In multiple years MBX reported negative net income over the last 5 years.
MBX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
MBX has a Return On Assets of 4.89%. This is amongst the best in the industry. MBX outperforms 86.36% of its industry peers.
With an excellent Return On Equity value of 6.65%, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
MBX has a better Return On Invested Capital (5.01%) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 6.65% | ||
| ROIC | 5.01% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MBX has a Profit Margin of 8.34%. This is amongst the best in the industry. MBX outperforms 90.91% of its industry peers.
MBX's Profit Margin has improved in the last couple of years.
MBX has a better Operating Margin (10.70%) than 90.91% of its industry peers.
In the last couple of years the Operating Margin of MBX has grown nicely.
MBX's Gross Margin of 56.11% is amongst the best of the industry. MBX outperforms 81.82% of its industry peers.
In the last couple of years the Gross Margin of MBX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.7% | ||
| PM (TTM) | 8.34% | ||
| GM | 56.11% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
MBX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
Compared to 5 years ago, MBX has more shares outstanding
MBX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.39 indicates that MBX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 3.39, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
The Debt to FCF ratio of MBX is 3.73, which is a good value as it means it would take MBX, 3.73 years of fcf income to pay off all of its debts.
MBX has a better Debt to FCF ratio (3.73) than 90.91% of its industry peers.
MBX has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.22, MBX is doing good in the industry, outperforming 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 3.73 | ||
| Altman-Z | 3.39 |
ROIC/WACC0.58
WACC8.63%
2.3 Liquidity
A Current Ratio of 6.62 indicates that MBX has no problem at all paying its short term obligations.
MBX has a Current ratio of 6.62. This is amongst the best in the industry. MBX outperforms 86.36% of its industry peers.
MBX has a Quick Ratio of 4.80. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX's Quick ratio of 4.80 is amongst the best of the industry. MBX outperforms 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 4.8 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -21.79% in the last year.
Measured over the past years, MBX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.58% on average per year.
The Revenue has been growing slightly by 2.73% in the past year.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-21.79%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-64.8%
Revenue 1Y (TTM)2.73%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-28.12%
3.2 Future
Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 51.83% on average per year.
Based on estimates for the next years, MBX will show a very strong growth in Revenue. The Revenue will grow by 21.86% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 38.00, the valuation of MBX can be described as expensive.
Based on the Price/Earnings ratio, MBX is valued cheaply inside the industry as 86.36% of the companies are valued more expensively.
MBX is valuated expensively when we compare the Price/Earnings ratio to 23.99, which is the current average of the S&P500 Index.
MBX is valuated reasonably with a Price/Forward Earnings ratio of 9.41.
Based on the Price/Forward Earnings ratio, MBX is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (20.35), we can say MBX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38 | ||
| Fwd PE | 9.41 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaper than 95.45% of the companies in the same industry.
MBX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MBX is cheaper than 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.01 | ||
| EV/EBITDA | 11.38 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has an outstanding profitability rating, which may justify a higher PE ratio.
MBX's earnings are expected to grow with 51.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (5/7/2025, 7:00:00 PM)
0.38
-0.01 (-2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners15.2%
Ins Owner ChangeN/A
Market Cap53.59M
Analysts80
Price Target0.92 (142.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38 | ||
| Fwd PE | 9.41 | ||
| P/S | 2.33 | ||
| P/FCF | 31.01 | ||
| P/OCF | 14.1 | ||
| P/B | 1.85 | ||
| P/tB | 2.16 | ||
| EV/EBITDA | 11.38 |
EPS(TTM)0.01
EY2.63%
EPS(NY)0.04
Fwd EY10.63%
FCF(TTM)0.01
FCFY3.22%
OCF(TTM)0.03
OCFY7.09%
SpS0.16
BVpS0.2
TBVpS0.18
PEG (NY)0.76
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.89% | ||
| ROE | 6.65% | ||
| ROCE | 6.95% | ||
| ROIC | 5.01% | ||
| ROICexc | 7.93% | ||
| ROICexgc | 9.71% | ||
| OM | 10.7% | ||
| PM (TTM) | 8.34% | ||
| GM | 56.11% | ||
| FCFM | 7.5% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 3.73 | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 124.49% | ||
| Cap/Sales | 9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.07% | ||
| Profit Quality | 89.93% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 4.8 | ||
| Altman-Z | 3.39 |
F-Score6
WACC8.63%
ROIC/WACC0.58
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.79%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-64.8%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)2.73%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-28.12%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y139.21%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y67.8%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y25.04%
OCF growth 3Y27.25%
OCF growth 5Y155.41%